FIGURE

Fig. 5

ID

ZDB-FIG-210119-15

Publication

El-Sahli et al., 2021 - A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

Combination of verteporfin-NP, paclitaxel-NP, and combretastatin-NP decreased ex vivo viability of PDX organotypic slice culture.

A, B Ex vivo viability analysis (Almar blue assay) of PDX (HCI-001) organotypic slice culture after 120-hr treatment with E-NP (empty-NP), P-NP (paclitaxel-NP, 5 nM), V-NP (verteporfin-NP, 250 nM), C-NP (combretastatin-NP, 5 nM), or different combinations. Data represents means ± SEM, n = 3, *P < 0.05, **P < 0.01.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Dis.